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Introduction
Many biological processes rely on the formation of protein–
protein complexes. These interactions are potential therapeutic
targets, but their diversity presents a significant challenge to
the development of small-molecule inhibitors.[1] These chal-
lenges are mainly due to proteins being relatively large and
having interaction surfaces that are, relative to enzyme active
sites, frequently rather featureless, and which often rely on in-
teractions involving noncontiguous amino acids. Moreover, in
contrast to the case for many enzymes and protein transmem-
brane channels, activity-based assays cannot usually be used
to identify inhibitors.[2] Despite these challenges, progress is
being made in targeting protein–protein interactions (PPIs).[3]
One of the methods showing significant promise is fragment-
based ligand discovery, in which binding fragments (Mr<
300 Da) are identified through biophysical screens and elabo-
rated into more potent molecules using structure-based ligand
design.[4]
In addition to the general challenges of PPIs, there is also
the potential issue of site selectivity. Many target proteins in-
teract with a number of different partners and may possess
multiple interaction sites. These problems of promiscuous
binding and multiple sites increase the risk of inhibitors also
disrupting beneficial interactions.[5] The nuclear transporter kar-
yopherin-a/importin-a, which is of increasing interest as an an-
ticancer and antiviral drug target,[6] exemplifies many of these
problems. In addition to having an essential role in mediating
the import of cargo proteins into the nucleus by binding to
nuclear localisation signals (NLSs) that are generally specific
clusters of positively charged amino acids,[7] importin-a also
regulates the function of the non-motor spindle assembly
factor TPX2 (target protein for Xenopus kinesin-like protein 2).
Importin-a is a banana-shaped protein that is constructed
from a series of 10 repeating structural motifs called armadillo
repeats ; it binds both the NLSs of nuclear import cargo pro-
teins and TPX2 using sites on its inner concave surface. All
NLSs bind to the major binding site, spanning armadillo re-
peats 1–4, and some also have a small additional contribution
from the minor site, spanning repeats 6–8.[8] TPX2, however,
binds primarily to the minor site of importin-a, thereby offer-
ing an opportunity for selectivity.
Both the major and minor sites on importin-a interact with
unstructured peptides on either NLSs or TPX2, which is in con-
trast to many other PPIs in which both partners are structured,
as observed, for example, with p53 or Bcl-xL, in which the bind-
ing motif is based on an a-helix.[9] Interactions based on such
unstructured peptides are more challenging to target, but
some progress has been described for the BRCA2–RAD51 inter-
action, for example.[10]
TPX2 is essential for the formation of an ordered spindle
and successful mitosis,[11] and its regulation by importin-a is
the major component of RanGTP-mediated spindle assembly
(Figure 1), a process on which cancer cells rely more heavily
than other cells.[12] As the transport and mitotic roles of impor-
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rupting other essential ones presents an additional challenge.
Herein we report how this might be achieved for the potential
anticancer target, the TPX2–importin-a interaction. Importin-
a is a nuclear transport protein that regulates the spindle as-
sembly protein TPX2. It has two binding sites—major and
minor—to which partners bind. Most nuclear transport cargoes
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tein–protein interaction.
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tin-a employ two different sites on the protein, the TPX2–im-
portin-a interaction has potential as an anticancer target, pro-
vided selectivity for the minor site over the major site can be
achieved. Previous work had focused on establishing the con-
sensus peptide sequence KRXF/Y/W[13] for recognition of the
minor site over the major site,[14] but no small molecules have
yet been designed specifically for this site. Herein we present
a fragment-based approach to the development of the first
site-specific ligands of the minor site TPX2–importin-a interac-
tion and provide validation for this approach to targeting com-
plex proteins such as importin-a.
Results and Discussion
Identification of importin-a binding fragments by ligand-
observed NMR screening of a thermal-shift-enriched library
Previous reports have shown that the hit rate for PPIs is typi-
cally lower than for enzyme targets, leading to the develop-
ment of modified versions of fragment-screening cascades to
minimise the amount of false negatives and positives.[10] For
TPX2–importin-a, a 1248-member ‘rule-of-three’-compliant[15]
fragment library was screened using fluorescence-based ther-
mal shift[16] to generate an enriched library of 140 compounds.
To prevent the autoinhibition that is crucial for expelling NLSs
in the nucleus, an importin-a construct (DIBB-importin-a) was
used from which the importin-b binding domain (IBB) had
been excised.[14] Compounds were excluded from the enriched
library if they were shown to denature or aggregate the pro-
tein at room temperature, or otherwise give strong negative
thermal shifts, as these may otherwise have generated false
positives in subsequent ligand-observed NMR experiments.
The enriched 140-fragment library was screened by the or-
thogonal ligand-observed NMR techniques saturation transfer
difference (STD),[17] water–ligand observed via gradient spec-
troscopy (WaterLOGSY)[18] and Carr–Purcell–Meiboom–Gill
(CPMG) spin-echo train sequence.[19] From the 140 compounds,
78 showed binding to importin-a, of which 35 showed dis-
placement by a 20-residue minor site binding TPX2 peptide
(Kd=350 nm) in at least one technique, suggesting that these
fragments were binding the TPX2 binding site on importin-a.
As an early study of the structure–activity relationship, 15
commercial compounds with scaffold similarity to 1 (as the
fragment showing the largest changes in binding and displace-
ment signals across all three ligand-observed NMR techniques;
see Supporting Information Figure S1) were screened, identify-
ing a further nine compounds with good binding and displace-
ment, giving a total of 44 fragments (structures listed in Sup-
porting Information Table S1). The 44 potential importin-
a minor site binding fragments identified in these screens
were then ranked by competitive isothermal titration calorime-
try (ITC).[20] As both thermal shift and NMR experiments were
performed at pH 8.0, competitive ITCs were also conducted at
this pH; however, all but two fragments (6 and 10) showed
only very weak (>15 mm competitive Kd) or no competition
with the TPX2 minor site binding peptide (Supporting Informa-
tion Table S2). To prioritise compounds for crystallography,
competitive ITC experiments were then performed at pH 6.0,
the pH to be used for the crystallographic soaking trials, re-
moving those that were not soluble to 10 mm in the ITC
buffer. From these studies 10 fragments (compounds 1–10)
Figure 1. Schematic of the role of importin-a and RanGTP in the regulation
of TPX2. In mitosis, after the nuclear membrane has been disassembled,
RanGTP is maintained at high concentration in the vicinity of chromatin. In
distal regions, Ran is predominantly in the GDP-bound form, leading to a gra-
dient of RanGTP concentration. RanGDP does not bind importin-b, allowing
it to bind the autoinhibitory IBB domain of importin-a that exposes the NLS
binding sites, and so allows importin-a to sequester and inhibit TPX2 activi-
ty. This ternary complex remains stable until it diffuses into the high concen-
tration of RanGTP near the chromosomes, where RanGTP binds to importin-
b, releasing the IBB domain and displacing TPX2, which thereby becomes
active, allowing for site-specific spindle assembly.
Table 1. Structures and Kd values of fragments 1–10 that were subse-
quently prioritised for crystallography.












[a] Determined by competitive ITC at pH 6.0; error values reported are
compound errors from the standard deviations of two replicate control
experiments and two replicate competitive fragment experiments.
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were shown to have Kd10 mm at pH 6.0 (Table 1) and were
prioritised for structural studies.
Structure of compound 1 shows selective binding to the
minor site through Glu396
Fragments 1–10 were individually soaked into unliganded crys-
tals of importin-a. X-ray datasets of resolution between 2.2
and 2.5 æ were collected for all except for fragments 9 and 10.
Inspection of the electron density maps only showed clear dif-
ference electron density for fragment 1, which was refined to
2.4 æ resolution. Attempts to co-crystallise the remaining frag-
ments under a variety of conditions were unsuccessful (Sup-
porting Information). Significantly, the co-crystal structure of
importin-a with fragment 1 revealed difference density for the
compound only in the minor site of importin-a with no signifi-
cant density peaks in the major site, suggesting that the initial
fragment demonstrated considerable site selectivity (Fig-
ure 2A).
Fragment 1 binds in the key minor site ‘hot spot’ positioned
such that the pyridine nitrogen atom is within hydrogen bond-
ing or salt-bridge distance (2.8 æ) of the carboxylate group of
the defining minor site residue Glu396 (where the crucial argi-
nine of TPX2 also forms interactions; Figure 2B–D). The aro-
matic rings of the fragment form a p–p stacking interaction
with Trp399, with the pyridine ring overlapping the indole ni-
trogen ring at a distance of 3.3 æ and an angle of 1018, and
the phenyl ring overlaying edges with the indole phenyl ring
at a distance of 3.3 æ and an angle of 1438. The p–p stacking
interaction between both rings of the fragment and the
Trp399 indole results in a twist between the fragment aromatic
rings with a torsion angle of 388 (Figure 2E).
Fragment merging with TPX2 lysine
After studying the overlay of fragment 1 on the previously re-
ported TPX2–importin-a structure,[14] compound 11 was syn-
thesised by merging the fragment with the lysine of the key
tetrapeptide KRXF/Y/W consensus sequence for TPX2 via an
amine linker using a reductive amination approach. Direct ITC
at pH 6.0 gave a Kd value of 4.0 mm for 11, a modest increase
on the Kd value of 8.7 mm for fragment 1. To understand how
11 was binding, a co-crystal structure of it bound to importin-
a (Figure 3A) was determined to 2.5 æ. This showed that 11
maintained the key pyridine Glu396 interaction as for com-
pound 1 (2.8 æ) as well as maintaining the p–p stacking inter-
action with Trp399 (the pyridine ring again overlapping the
indole nitrogen ring at a distance of 3.5 æ and an angle of 968
and the phenyl ring overlaying edges with the indole phenyl
ring at a distance of 3.3 æ and an angle of 1188). These
changes result in a good overlay of the fragment portion of 11
with the structure of 1 (Supporting Information Figure S2);
once again the torsion angle between the two aromatic rings
was 408 similar to fragment 1 (388), suggesting the lysine was
able to reach the new pocket without changing the fragment
orientation. This suggests that the fragment, despite its low af-
finity, is a good anchor in this key hotspot. As for the structure
of 1, there was no density in the importin-a major site for 11,
suggesting that the new ligand maintains specificity to the
minor site. The structure of 11 showed reasonable density for
the amine of the lysine group, indicating that it is reaching the
desired pocket and forming a hydrogen bond with the carbon-
yl group of Gly323 (3.0 æ). Despite these additional interac-
tions, the increase in affinity of 11 for importin-a was modest,
possibly due to the alternative orientation of the lysine back-
bone (~1608 flip) relative to the native TPX2 peptide (Fig-
ure 3A).
Extending the peptide chain
To assess whether the orientation of the lysine backbone in 11
was important, and to probe other interactions in the minor
site, a longer merged peptide of the form fragment-KGTF 12
(with glycine replacing the arginine, the interaction of which is
mimicked by the N-terminal fragment and the TF from human
Figure 2. Structural validation of fragment hit 1. A) Compound 1 (yellow)
bound specifically to the minor site of importin-a (grey surface). 2Fo¢Fc den-
sity for compound 1 is shown at 1.0 s (blue mesh). Red sticks represent the
minor and major site binding portions of the cargo protein nucleoplasmin
from the PDB structure 1EJY.[30] B) Fragment 1 (yellow) with the 2Fo¢Fc den-
sity shown contoured around the ligand at 1.0 s (blue mesh) bound to the
importin-a minor site (green ribbon and sticks). C) Fragment 1 bound to the
importin-a minor site without electron density. D) Fragment 1 structure
overlaid with the key TPX2 residues (magenta) from the TPX2–importin-
a crystal structure 3KND.[14] E) Schematic to show the key interactions with
fragment 1: red residues make hydrogen bonding or salt-bridge contacts,
blue residues are involved in p–p stacking interactions, and residues denot-
ed by black circles form nonpolar interactions with the ligand.
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TPX2) was synthesised and its binding analysed. Direct ITC of
12 at pH 6.0 gave a Kd value of 3.3 mm, showing no improve-
ment on 11. The co-crystal structure of 12 bound to importin-
a was determined to 2.3 æ resolution (Figure 3B). Analysis of
the ligand conformation revealed that the extended peptide
had caused the lysine backbone to undergo a ~1508 flip to
orient with the native TPX2 tetrapeptide, while the fragment
maintained its interaction with Glu396 (hydrogen bonding dis-
tance of 2.8 æ) and Trp399 (p–p stacking distance of pyridine
to indole 3.3 æ with an angle of 948 ; Figure 3B and Supporting
Information Figure S2). Comparing the lysine of 12 with that of
11 and TPX2, there is closer alignment with TPX2, as the lysine
amine makes hydrogen bonds to the carbonyls of Val321 and
Asn361 and the hydroxy group of Thr328 rather than the car-
bonyl of Gly323. In addition, the interactions with the peptide
backbone made by the side chains of Asn361 and Trp357 are
the same as observed for the peptide. However the phenylala-
nine of 12 is poorly defined and appears to be in a hydropho-
bic pocket defined by Lys353 and Glu354 as opposed to form-
ing p–cation stacking interactions with Arg315 as for the aro-
matic residue of TPX2. These differences in the alignment of
the peptide backbone of 12 compared with the TPX2 repre-
sent a potential explanation for its relatively modest affinity
(Figure 3B).
Removal of the phenyl ring of the biaryl scaffold
To explore the effect of changing the biaryl fragment scaffold,
an unnatural amino acid incorporating a pyridine was synthes-
ised and coupled to give the peptidic KXTF 13. Direct ITC of
13 gave a Kd value of 3.9 mm, analogous to 12. The 2.1 æ reso-
lution structure of 13 bound to importin-a revealed a much
better structural overlay of the peptide backbone with that of
TPX2 than 12, with the exception of the phenylalanine that re-
mains poorly defined. As with previous compounds, the pyri-
dine maintains the interactions with Glu396 (hydrogen bond
3.0 æ) and Trp399 (p–p stacking distance of pyridine to indole
3.2 æ with an angle of 898), even without the biaryl scaffold
(Figure 4C).
Strikingly, for the first time in this study, analysis of the
major site showed clear density for another molecule of 13
binding (Figure 4A). The interaction at the major site involved
inducing a 618 rotation of Trp184 and a 1378 rotation of
Trp231, forming a cryptic pocket with a depth of ~2.7 æ (Fig-
ure 4D). The pyridine of 13 fills this new cryptic pocket form-
ing face-to-face p–p stacking interactions with Trp184 and
Trp231, at distances of 3.3 and 3.4 æ, respectively (Figure 4D).
The rotation of Trp184 also opens a hydrophobic ‘shelf’ on
which the phenylalanine of 13 is positioned to form edge-to-
face interactions with Trp184 (3.6 æ) and Trp142 (3.7 æ). This
result was highly surprising, as no aromatic or hydrophobic
containing peptides have been found to bind the major site
without long chains of basic flanking residues either side of
the central tetrapeptide, with classical major site cargoes
having NLSs typified by the SV40 sequence (Figure 4F).[21] In
addition, this suggested that the biaryl scaffold was a source
of selectivity for compounds 1, 11, and 12, as its rigidity pre-
sumably prevents the pyridine from orienting to open the
cryptic pocket as well as introducing another unfavourable ar-
omatic into a polar region of the major site that cannot be
masked by other aromatic residues of the protein.
Linker SAR increases potency and structures identify a new
pocket in the minor site
Having established that the biaryl scaffold appears to be the
source of selectivity for the minor site in this series of com-
pounds, the crystal structures and docking results were used
to design a variety of compounds to explore the structure–ac-
tivity relationship (SAR) of various fragment–lysine connectivi-
ties. The aim was to minimise the strain around the lysine link-
age, allowing the backbone flip and improving potency
(Table 2). The amide-linked compound 14 had Kd>10 mm by
direct ITC, suggesting that its decreased flexibility was deleteri-
ous. Changing the stereoisomer 15 of the lysine gave no
change in affinity relative to 11, whereas moving the lysine
from the para to the meta position of the phenyl ring of the
biaryl 16 gave a modest improvement in potency. To explore
other vectors for the lysine while maintaining similarity to the
Figure 3. Structures of compounds A) 11 and B) 12 bound to the minor site
of importin-a. Top: ligand (yellow) with the 2Fo¢Fc density shown contoured
around the ligand at 1.0 s (blue mesh) bound to the importin-a minor site
(green ribbon and sticks). Middle: ligand bound in minor site without densi-
ty. Bottom: ligand structure overlaid with the key TPX2 residues (magenta)
from the TPX2–importin-a crystal structure 3 KND.[14]
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phenyl, the second ring was replaced with a thiophene (in 17)
resulting in a further increase in potency and the first sub-milli-
molar compound. X-ray co-crystal structures were solved for all
the compounds 14–17 bound to importin-a with resolution in
the range of 2.0–2.6 æ showing the resultant changes in lysine
position and backbone alignment (Figure 5).
The inclusion of a biaryl scaffold in all cases resulted in selec-
tivity for the minor site, and overlay with the original fragment
1 suggested that these remained ‘anchors’ for the Glu396 in-
teraction despite the changes to the lysine (Supporting Infor-
mation Figure S2). Both 16 and 17 showed binding in
a second pocket of the minor site with an extra compound
forming a p–p stacking interaction with Trp357 (3.4 and 4.0 æ,
respectively) and a water-mediated hydrogen bond to Glu354
(2.4 æ to water then 2.9 æ to glutamate, and 2.0 æ to water
then 2.8 æ to glutamate, respectively), in addition to binding in
the Glu396 pocket. In both cases the density for the lysine por-
tion of this second compound was unresolved. For the ligands
interacting with Glu396, although the fragment portions of
Table 2. Structures and Kd values for compounds 11–17.









[a] Determined by direct ITC at pH 6.0; errors reported are the standard
deviations of three replicate runs.
Figure 4. Compound 13 bound to importin-a minor and major sites.
A) Compound 13 (yellow) with the 2Fo¢Fc density shown contoured around
the ligand at 1.0 s (blue mesh) bound to both the minor and major sites of
importin-a (grey surface). B) Structure of compound 13. C),D) Compound 13
(yellow) with the 2Fo¢Fc density bound to the importin-a minor (C) and
major (D) sites (top); ligand bound in minor (C) and major (D) sites without
density (bottom). E) Compound 13 structure in minor site overlaid with the
key TPX2 residues (magenta) from the TPX2–importin-a crystal structure
3KND.[14] F) Compound 13 structure overlaid with the key SV40 residues
(cyan) from the SV40–importin-a structure, 1EJL.[30] Grey residues show the
positions of the tryptophans in the SV40 structure.
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both 16 and 17 overlay well, the lysines behave quite differ-
ently. While the lysine amine of 17 forms hydrogen bonds
with the carbonyls of Val321 (2.9 æ) and Gly323 (3.2 æ) in the
lysine pocket, that of 16 does not reach into the lysine pocket,
but instead reorients toward the solvent due to the interaction
of the amide with the side chain of Asn403 via a water-mediat-
ed hydrogen bond (2.4 æ then 3.5 æ). Such changes perhaps
explain the small differences in potency observed between
these compounds. Despite the changes in interaction, the in-
creases in affinity remain modest and suggest that the lysine
may not make as great a contribution to affinity as was indicat-
ed from previous studies with peptide ligands.[13,21]
Finally, the two compounds of 16 and 17 seen binding in
close proximity in the importin-a minor site in their co-crystal
structures could permit novel fragment linking or growing
strategies, between the two biaryl binding sites, moving away
from the more flexible lysine and potentially increasing affinity
for the minor site.
Conclusions
PPIs are potential targets in a wide range of diseases, but tar-
geting interactions that are based on unstructured peptides re-
mains a significant challenge, in addition to the problems asso-
ciated with achieving sufficient specificity. The potential anti-
cancer target interaction between TPX2 and importin-a pro-
vides a platform for a pilot study for the use of fragment-
based ligand discovery against such targets. A ligand-observed
NMR screen of a thermal-shift-enriched fragment library identi-
fied several importin-a binding fragments that appeared to
bind in the minor site. Structural studies showed that, despite
its low affinity, fragment 1 bound specifically in the minor site
of importin-a at the key residue Glu396. Information from this
structure, as well as docking studies, facilitated the synthesis of
a range compounds to probe the contributions made by differ-
ent groups to affinity for the minor site binding pocket. It was
shown that the biaryl scaffold of the fragment is key to the
specificity of the compounds for the minor site over the major
site, as well as showing that the lysine pocket of the minor site
may not make as large a contribution to binding affinity as
was thought from previous peptide-based studies. These find-
ings are important considerations for the further development
of probes and inhibitors of the TPX2–importin-a site.
These results provide a proof of concept for the use of
a fragment-screening cascade in targeting specific sites on
multiple site proteins, even when they are based on the bind-
ing of unstructured peptides. We have shown fragments to be
useful probes in identifying the key binding interactions of
open PPI sites as well as achieving and explaining specificity
for one site over another. Furthermore, the structures showed
that the fragment portion of all the compounds maintained
the key interaction with Glu396 despite changes in the lysine
or larger peptide positioning, highlighting the effectiveness of
fragments as anchors in key PPI hot spots.
Experimental Section
Fragment library design : The fragment library consisted of 1248
commercial fragments based around a core of compounds from
Maybridge, supplemented by a selection of compounds chosen to
maximise chemical functionality from commercial suppliers Acros
Organics, Apollo Scientific, and Sigma–Aldrich. Fragments were
stored as 100 mm solutions in [D6]DMSO 96-well stock plates.
Protein expression and purification : The protein construct used
in this study is a truncated form of Mus musculus importin-a1
(KPNA2, Accession code: NM_010655) covering residues 70–529,
lacking the N-terminal IBB domain: DIBB-importin-a.[14,22] The pro-
tein has >97% sequence similarity with the Homo sapiens variant
(Supporting Information Figure S4). The protein was expressed
from an in-house modified pET-30a plasmid (EMD Bioscience) with
a TEV cleavable His6/S-tag that was cleaved during purification; full
details are given in the Supporting Information.
Thermal shift fragment library enrichment : The changes in the
thermal shift of importin-a caused by fragments were assessed
using either a Roche LightCycler with opaque PCR plates and clear
plastic sealing film (Roche) or on a Bio-Rad Thermocycler with clear
PCR plates and flat cap strips (Bio-Rad). Sypro Orange (5000Õ solu-
Figure 5. Crystal structures of compounds A) 14, B) 15, C) 16, and D) 17
binding to the importin-a minor site. Left : compound structure; middle:
compound (yellow) bound to the minor site of importin-a (green ribbon
and sticks) with the 2Fo¢Fc density for each compound contoured around
the ligand at 1.0 s (blue mesh); right: compound bound to the minor site
without density.
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tion, Invitrogen) was diluted 1:2000 in standard buffer (50 mm
Tris·HCl pH 8.0, 200 mm NaCl, 1 mm DTT) before addition of impor-
tin-a to a concentration of 2 mm and filling assay wells to a volume
of 100 mL. The standard Tris buffer was selected from a buffer
screen, as it showed the greatest thermal stabilisation of importin-
a. Fragments were screened at a final concentration of 5 mm with
5% DMSO. The fluorescence readout was monitored from 35–60 8C
(LightCycler) or 25–60 8C (Thermocycler), both at 0.01 8Cs¢1. All
samples were measured in duplicate. Fragments with a negative
thermal shift greater than twice the negative standard deviation of
each plate’s negative controls wells (5% DMSO) were removed
from the enriched library.
Ligand-observed NMR screening : The three ligand-observed tech-
niques—STD, CPMG, and WaterLOGSY—were performed on either
a Bruker Avance 500 MHz with TCI cryoprobe or on a Bruker
Avance 700 MHz spectrometer with a TXI cryoprobe. All samples
were made to a total volume of 200 mL and added to 3 mm capilla-
ry tubes (Bruker) before inserting into standard or thick-walled
NMR tubes (Bruker). All samples were made to volume in standard
protein buffer with 10% D2O and 20 mm TSP. Screens were con-
ducted with fragments at 2 mm from [D6]DMSO stock plates,
giving a final DMSO concentration of 2%. Binding was determined
on observation of a change in fragment signals in the presence of
20 mm importin-a, relative to a control sample containing only
buffer and no protein. If found to bind importin-a, a displacer
sample was made by addition of 40 mm TPX2 (IIKPFNLSKGKKRTF-
DEAAS) peptide (Designer Bioscience) direct to the protein sample
and displacement noted if the fragment signals showed a return
to those seen in the control sample.
Isothermal titration calorimetry : All experiments were performed
on a Microcal ITC200 instrument (GE Healthcare) at 25 8C. All ITCs
were performed at pH 6.0 using ITC buffer (100 mm citrate pH 6.0,
200 mm NaCl, 10% DMSO). Fragment ITCs were performed using
the competitive ITC technique following the procedure and formu-
la described by Zhang et al.[20] (Supporting Information). Briefly, the
titration of 200 mm 20-amino acid TPX2 to 25 mm importin-a 10%
DMSO at pH 6.0 (average Kd=1.0 mm) was compared directly with
the same titration in the presence of the fragment at 5 or 10 mm.
Direct ITCs were performed for elaborated compounds at pH 6.0 in
ITC buffer titrating 10 mm compound into 25 mm protein. Com-
pounds that showed double binding in crystal structures (13, 16,
and 17) had their ITCs fitted using a one-site binding model, as
this gave the best curve fitting, suggesting the second binder re-
mains relatively weak. Experimental parameters are described fully
in the Supporting Information.
Crystallisation and crystallographic methods : Crystals of unli-
ganded DIBB-importin-a were grown using hanging-drop vapour
diffusion in 24-well Linbro plates (Hampton Research) with 4 mL
drops of 100 mm DIBB-importin-a1 at 1:1 protein/precipitant
volume ratio (optimal precipitant conditions: 0.1m citrate pH 6.0,
1.05–1.20m ammonium sulfate, 20–40 mm DTT) and streak-seeding
from an DIBB-importin-a seed crystal plate 18 h after sealing the
wells. Crystals reached their maximum size after 1–2 weeks, when
they were soaked in solutions of fragment (100 mm or saturating
concentration) in crystallisation buffer supplemented with 10%
DMSO for between 30 min and 5 h. Crystals were then briefly ex-
posed to crystallisation buffer (with half fragment concentration
and an additional 10% glycerol) as a cryoprotectant and flash
cooled at 100 K in liquid nitrogen. X-ray data were collected at the
Diamond Light Source or European Synchrotron Radiation Facility.
All datasets were processed and reduced using XDS[23] and AIM-
LESS.[24] The unit cells of these crystals were sufficiently close to
that of murine DIBB-importin-a1 in the Xenopus–mouse TPX2–im-
portin-a structure;[14] PDB ID 3KND) to enable rigid body refine-
ment, after which coordinates were refined using iterative cycles of
PHENIX,[25] CCP4,[26] and COOT.[27] Electron density maps were then
inspected for difference density corresponding to the soaked li-
gands, which were then built into the model manually using COOT,
with restraints generated in PHENIX. The resulting models were fur-
ther refined with CCP4 or PHENIX, as well as adding waters and
ions from the crystallisation conditions. The stereochemistry of the
structure was finally assessed using MolProbity.[28] Molecular graph-
ics were generated using the PyMOL Molecular Graphics System,
version 1.6.0.0, Schrçdinger LLC. Data collection and refinement
statistics are shown in Table S3 of the Supporting Information. At-
tempts at co-crystallisation are described in the Supporting Infor-
mation.
Compound docking : All compounds were docked into an unli-
ganded structure of mouse DIBB-importin-a1. The protein was pre-
pared in Discovery Studio Visualizer (Release 3.5, Accelrys Software
Inc. , San Diego, CA, USA) by removal of crystallographic waters
and addition of hydrogens before selecting the coordinates of the
key minor site residue Glu396. Compounds to be docked were
loaded as .mol files into Discovery Studio Visualizer where hydro-
gens and relevant charges were added before the structures were
minimised to relax bond lengths and fix bond angles. Ligands
were docked into the protein in a radius of 13 æ around Glu396
using GOLD 5.1[29] using default slow docking settings with 25 runs
for each ligand. Figures of the ten lowest-energy docked positions
of each were exported and subjected to visual analysis.
Synthetic chemistry : General directions for the synthesis of the
compounds described as well as their spectroscopic analyses are
supplied in the Supporting Information. The purity of all com-
pounds tested for binding to importin-a was assessed by LCMS or
HPLC and is >95% unless otherwise stated.
Accession numbers : The coordinates and structure factors for the
mouse–mouse TPX2–importin-a structure used to inform com-
pound synthesis, as well as importin-a compound structures 1, 11,
12, 13, 14, 15, 16, and 17 have been deposited in the RCSB Protein
Data Bank (www.pdb.org) under the PDB ID codes: 4U54, 4U5L,
4U5N, 4U5S, 4U58, 4U5O, 4U5U, and 4U5V respectively.
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